Identifying Barriers to Cellular Therapy
Prospective Multi-Center Study to Identify Barriers to Cellular Therapies in Patients With Plasma Cell Disorders PROACT PCD
- Transplant Service
- 23-166
What will happen during the trial?
This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Observational Trial
- Enrollment
- 400 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Trial Type
- Observational
- Last Update
- 2 months ago
- SparkCures ID
- 1797
- NCT Identifier
- NCT06126341
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.